SNTI SENTI BIOSCIENCES INC

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

Moderated webcast fireside chat with members of Senti management and Chardan senior research analyst, Geulah Livshits, PhD on Monday, June 9th at 3:00 PM ET

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will participate in a on Monday, June 9, 2025 at 3:00 PM ET.

For the fireside chat, , and of Senti Biosciences will join Chardan senior research analyst, Geulah Livshits, PhD for the moderated discussion.

Register for the event .

About Senti Bio



Senti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.



Availability of Other Information About Senti Biosciences, Inc.



For more information, please visit the Senti Bio website at or follow Senti Bio on (@SentiBio) and (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on and . The information that we post on our website or on or could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Investor Contact:

JTC Team, LLC

Jenene Thomas

(908) 824-0775



EN
06/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SENTI BIOSCIENCES INC

 PRESS RELEASE

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms N...

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2025 and provided a summary of recent pipeline and corporate highlights. “Our team has continued to advance SENTI-202...

 PRESS RELEASE

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study ...

Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia Continued progress positions Company to report topline data for Phase 1 clinical trial of SENTI-202 before year-end SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced it has confirmed the recom...

 PRESS RELEASE

Senti Biosciences Participates in the Virtual Investor “What’s Your St...

Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference – Video webcast now available on-demand SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that of Senti, participated in the . As part of the event, Dr. Lu dove deeper into his dedication to the Company, how he got to where he is today and provided insight int...

 PRESS RELEASE

Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give...

Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum Presentation to highlight how Senti Bio's novel first-in-class logic-gated CAR-NK cell therapy kills leukemic cells while protecting healthy bone marrow SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the being held...

 PRESS RELEASE

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to...

Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Bryan Baum to its Board of Directors. Mr. Baum is a serial entrepreneur and investor and is the Co-Founder and Managing Partner of K5 Global. His portfolio includes category-defining companies ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch